Conjugation of Dasatinib with MHI‐148 Has a Significant Advantageous Effect in Viability Assays for Glioblastoma Cells
Abstract
We hypothesized that conjugation of the near‐infrared dye MHI‐148 with the anti‐leukemia drug dasatinib might produce a potential theranostic for glioblastoma. In fact, the conjugate was found to bind the kinases Src and Lyn, and to inhibit the viability of a glioblastoma cell line with significantly greater potency than dasatinib alone, MHI‐148 alone, or a mixture of dasatinib and MHI‐148 at the same concentration. It was also used to successfully image a subcutaneous glioblastoma tumor in vivo.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Aug 07, 2019
- Source ID
- 10.1002/cmdc.201900356
Entities
People
- Kathryn Pflug
- Kevin Burgess
- Raquel Sitcheran
- Syed Muhammad Usama
- Zhengyang Jiang
Organizations
- Cancer Prevention and Research Institute of Texas
- National Science Foundation
- Robert A. Welch Foundation
- Texas A&M University
- United States Department of Defense
- Yusuf Hamied Department of Chemistry